Please login to the form below

Not currently logged in
Email:
Password:

methylphenidate

This page shows the latest methylphenidate news and features for those working in and with pharma, biotech and healthcare.

UCB's $1.53bn generics sale falls through

UCB's $1.53bn generics sale falls through

formulation of methylphenidate hydrochloride for attention-deficit hyperactivity disorder (ADHD). ... While we are working on clarifying the situation around methylphenidate ER we will continue the divestiture process for Kremers Urban," said UCB chief

Latest news

  • J&J earnings leap on buoyant pharma sales J&J earnings leap on buoyant pharma sales

    On the downside, generic competition continued to take its toll on older drugs such as gastrointestinal Aciphex/Pariet (rabeprazole) and attention-deficit hyperactivity disorder drug Concerta (methylphenidate).

  • Buoyant pharma sales drive J&J's Q3 results Buoyant pharma sales drive J&J's Q3 results

    On the downside, attention-deficit hyperactivity disorder (ADHD) treatment Concerta (methylphenidate) continued to succumb to generic competition, losing $110m in sales compared to the third quarter of 2012 to come in

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    In the absence of Adderall XR, the price of rival ADHD brand Concerta (methylphenidate) from Johnson &Johnson would be around 5 per cent higher - at $101 per month instead of

  • Think positive: the rise of 'smart drugs' Think positive: the rise of 'smart drugs'

    which are reported with both methylphenidate and modafinil, says Mehta, who freely admits this hypothesis is untested. “ ... And with decades of experience with methylphenidate and modafinil there does not seem to be any major health issues surrounding

  • OTC recovery helps J&J in first-quarter OTC recovery helps J&J in first-quarter

    On the downside, attention-deficit hyperactivity disorder (ADHD) product Concerta (methylphenidate) and gastrointestinal drug Aciphex/Pariet (rabeprazole) continued to be affected by generic competition.

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

  • Pharma deals during October 2012 Pharma deals during October 2012

    Established products – new formulations. Pfizer's acquisition of NextWave Pharmaceuticals bolsters its established products business unit bringing Quillivant XR (methylphenidate hydrochloride), which recently secured FDA approval for attention

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics